Prelude
Latest round
- Series F
Last raised
- Jan 2022
Total raised
- $9.3M
Investors
- 1
About Prelude
Prelude Corp. specializes in precision medicine through the development of diagnostic tests for cancer treatment. The company was founded in 2009 in Laguna Hills, US, and has completed a total of 3 deals.PreludeDx specializes in the development and commercialization of innovative diagnostic tests for breast cancer, specifically targeting patients diagnosed with ductal carcinoma in situ (DCIS). The company's flagship product, DCISionRT, is a biomarker test that identifies distinct risk profiles among DCIS patients and predicts their benefit from radiation therapy. This test enables healthcare providers to tailor treatment plans based on individual recurrence risks, helping to determine which patients can safely forgo radiation therapy. PreludeDx serves a diverse client base that includes oncologists, healthcare institutions, and cancer treatment centers primarily in the United States, with its offerings expanding into international markets as awareness and demand for precision medicine grow.PreludeDx generates revenue through the provision of its diagnostic services, particularly the DCISionRT test. Transactions typically occur on a direct-to-consumer basis, where healthcare providers order the tests for their patients, and insurance reimbursement processes often facilitate payment. The company establishes partnerships with healthcare organizations to enhance adoption and integration of their diagnostic solutions into existing treatment protocols. Pricing structures for the DCISionRT test reflect its proprietary nature, and the firm utilizes a B2B model, collaborating with medical institutions to streamline the ordering and delivery of its services.In January 2022, Prelude Corp. The company is focused on expanding its offerings, specifically aiming to introduce new diagnostic tests and enter additional international markets to enhance patient access by 2025.
Who invested in Prelude
1 investor across 1 round
See all investors in Prelude
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series F
Jan 31, 2022
Amount
$9.3M
Investors
Questions about Prelude
Who invested in Prelude?
Prelude has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Prelude raised?
Prelude has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Prelude last raise money?
Prelude's most recent round on record is a Series F, in Jan 2022.
What does Prelude do?
Prelude is a medical devices & equipment company.
Where is Prelude headquartered?
Prelude is headquartered in Laguna Hills, US.
Which VCs invest in companies like Prelude?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back medical devices & equipment companies at Prelude's stage. Their profiles are linked below.
VCs backing medical devices & equipment startups at Series F
Raising like Prelude? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.